BioVie's Bezisterim Full Dataset From Phase 2a Trial In Parkinson's Disease, Patients Experienced Significant Improvements In Both Non-Motor Symptoms And Motor Control While Placebo-Treated Patients Worsened

5/22/24 8:14:37 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BIVI alert in real time by email

Full Dataset from Phase 2a trial in Parkinson's Disease suggest patients treated with bezisterim experienced significant improvements in both non-motor symptoms and motor control while placebo-treated patients worsened

Improvements in non-motor symptoms correlated with improvements

in motor symptoms for Parkinson's Disease patients

Get the next $BIVI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BIVI

Date	Price Target	Rating	Analyst
7/22/2022	$7.00	Overweight	Cantor Fitzgerald
11/30/2021	$50.00 → $27.00	Buy	B. Riley Securities

More analyst ratings

ThinkEquity Initiates Coverage On BioVie with Buy Rating, Announces Price Target of $3
ThinkEquity analyst Ashok Kumar initiates coverage on BioVie (NASDAQ:BIVI) with a Buy rating and announces Price Target of $3.
7/1/24 6:52:55 AM ET
$BIVI
Biotechnology: Pharmaceutical Preparations
Health Care
BioVie Presents Protocol Design Of Upcoming SUNRISE-PD Phase 2 Trial Of Bezisterim In Patients With Early Parkinson's Disease At ATMRD 2024
SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson's disease who are naïve to carbidopa/levodopaAdditional presentation at congress highlighted data from earlier Phase 2a trial of bezisterim in Parkinson's disease that helped inform SUNRISE-PD trial design CARSON CITY, Nev., June 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced data from two presentations at the Advanced Therapeutics in Movement and Related Disorders Con
6/25/24 8:11:51 AM ET
$BIVI
Biotechnology: Pharmaceutical Preparations
Health Care
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Entero Therapeutics (NASDAQ:ENTO) stock rose 10.2% to $2.6 during Monday's after-market session. The market value of their outstanding shares is at $7.1 million. Akanda (NASDAQ:AKAN) stock rose 7.74% to $2.92. The company's market cap stands at $5.5 million. LifeMD (NASDAQ:LFMD) stock rose 5.81% to $8.0. The market value of their outstanding shares is at $327.0 million. Purple Biotech (NASDAQ:PPBT) shares rose 5.79% to $0.58. The company's market cap stands at $15.2 million. Salarius Pharmaceuticals (NASDAQ:SLRX) shares rose 5.29% to $0.44. The market value of their outstanding shares is at $2.0 million. Compass Therapeutics (NASDAQ:CMPX) shares increased by 4.95% to $1.27. The
6/10/24 4:31:12 PM ET
$AKAN
$BIVI
$CMPX
$ENTO
Medicinal Chemicals and Botanical Products
Health Care
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)

$BIVI
Leadership Updates

Live Leadership Updates

BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID
CARSON CITY, Nev., June 04, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of a long COVID Advisory Board that will provide the Company with strategic guidance on the design and execution of a Phase 2b trial in patients with long COVID, with funding from the U.S. Department of Defense. Long COVID is a condition in which symptoms of COVID-19, the acute respiratory disease caused by the SARS-CoV-2 virus, persist for an extended period of time, generally three months or
6/4/24 8:00:00 AM ET
$BIVI
Biotechnology: Pharmaceutical Preparations
Health Care
BioVie Announces the Appointment of a New Chief Medical Officer
RENO, Nev., Nov. 01, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurodegenerative disease - announced today the appointment of Joseph M. Palumbo, MD, LFAPA, MACPsych, as the Company's new Chief Medical Officer. In this role Dr. Palumbo will oversee the Company's clinical development and operations activities, including the advancement of NE3107, an oral small molecule, blood-brain permeable modulator of ERK and NFkB (e.g. TNF transcription) expected to modulate neuroinflammation and insulin resistance, while still facilitating the homeostatic function inherent to their mechanisms (
11/1/21 8:00:00 AM ET
$BIVI
Biotechnology: Pharmaceutical Preparations
Health Care
BioVie Acquires Biopharma Assets from Privately Held NeurMedix
Includes Pivotal Phase 3 Alzheimer's Asset NE3107 Cuong V. Do Named CEO of The New BioVie Conference Call Scheduled for April 27, 2021 at 5:00PM EDT SANTA MONICA, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for chronic debilitating liver diseases, today announced the acquisition of the biopharmaceutical assets of NeurMedix, Inc., (NeurMedix), a San Diego based privately held clinical-stage pharmaceutical company focused on novel therapeutic assets for the treatment of neurodegenerative and neurological disorders, as well as certain cancers. Under the terms of the agreeme
4/27/21 4:05:00 PM ET
$BIVI
Biotechnology: Pharmaceutical Preparations
Health Care

$BIVI
Press Releases

Fastest customizable press release news feed in the world

BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
CARSON CITY, Nev., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract on the design of its planned Phase 2 trial evaluating bezisterim in Long COVID has been accepted as a poster presentation at the Demystifying Long COVID International Conference, November 21st & 22nd 2024, in Barcelona Spain. The planned Phase 2 study, which is fully funded by a grant from the U.S. Department of Defense (DOD), is a double-blind, randomized (1:1), placebo-controlled, multicenter t
11/20/24 8:00:00 AM ET
$BIVI
Biotechnology: Pharmaceutical Preparations
Health Care
BioVie's Upcoming Parkinson's Disease Clinical Trial is Fully Funded
CARSON CITY, Nev., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, is pleased to announce that the upcoming PD-202 A Double-Blind, Randomized, Placebo-controlled, Study of Bezisterim in Subjects with Early Parkinson's Disease is now fully funded. Favorable capital market conditions last week enabled the company to raise over $15 million from secondary offerings, and the proceeds allow the Company to fund fully the costs of this upcoming clinical trial. The trial is expected to start in ea
11/4/24 8:00:00 AM ET
$BIVI
Biotechnology: Pharmaceutical Preparations
Health Care
BioVie Inc. Announces Closing of Registered Direct Offering
CARSON CITY, Nev., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced registered direct offering of 1,146,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.83 per share. The gross proceeds to the Company from the offering are $3,243,180, before deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from the offering primarily for working cap
10/29/24 4:05:00 PM ET
$BIVI
Biotechnology: Pharmaceutical Preparations
Health Care

BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
CARSON CITY, Nev., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract on the design of its planned Phase 2 trial evaluating bezisterim in Long COVID has been accepted as a poster presentation at the Demystifying Long COVID International Conference, November 21st & 22nd 2024, in Barcelona Spain. The planned Phase 2 study, which is fully funded by a grant from the U.S. Department of Defense (DOD), is a double-blind, randomized (1:1), placebo-controlled, multicenter t
11/20/24 8:00:00 AM ET
$BIVI
Biotechnology: Pharmaceutical Preparations
Health Care
BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin
Patents covering BioVie's terlipressin liquid formulation now secured in the United States, India, Japan and Chile, and are pending in eight additional markets Liquid formulation has demonstrated room-temperature stability for up to 24 months, representing an important advantage for treating patients with cirrhosis and ascites in the home-care setting CARSON, Nev., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it has received a Notice of Allowance from the Japan
10/15/24 8:00:00 AM ET
$BIVI
Biotechnology: Pharmaceutical Preparations
Health Care
BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 11, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and Genetic Technologies Limited (NASDAQ:GENE)(ASX:GTG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessGenetic Technologies: https://www.redchip.com/assets/access/gene_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical prog
10/11/24 9:00:00 AM ET
$BIVI
$BOXL
$GENE
Biotechnology: Pharmaceutical Preparations
Health Care
Other Consumer Services
Real Estate

BioVie's Bezisterim Full Dataset From Phase 2a Trial In Parkinson's Disease, Patients Experienced Significant Improvements In Both Non-Motor Symptoms And Motor Control While Placebo-Treated Patients Worsened

Chat with this insight

Recent Analyst Ratings for $BIVI

$BIVI Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by BioVie Inc.

Amendment: SEC Form SC 13D/A filed by BioVie Inc.

SEC Form SC 13D/A filed by BioVie Inc. (Amendment)

$BIVI SEC Filings

SEC Form S-8 filed by BioVie Inc.

SEC Form S-1 filed by BioVie Inc.

SEC Form 10-Q filed by BioVie Inc.

$BIVI Market Insights

Live Market Insights

ThinkEquity Initiates Coverage On BioVie with Buy Rating, Announces Price Target of $3

BioVie Presents Protocol Design Of Upcoming SUNRISE-PD Phase 2 Trial Of Bezisterim In Patients With Early Parkinson's Disease At ATMRD 2024

12 Health Care Stocks Moving In Monday's After-Market Session

$BIVI Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Palumbo Joseph M covered exercise/tax liability with 33,952 shares and was granted 116,000 shares, increasing direct ownership by 221% to 119,196 units (SEC Form 4)

Chief Financial Officer Kim Joanne Wendy covered exercise/tax liability with 23,202 shares and was granted 73,000 shares, increasing direct ownership by 113% to 93,940 units (SEC Form 4)

President & CEO Do Cuong V covered exercise/tax liability with 4,953 shares, covered exercise/tax liability with 46,953 shares and was granted 168,000 shares (SEC Form 4)

$BIVI Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Do Cuong V bought 10,000 shares (SEC Form 4)

Do Cuong V bought $17,800 worth of shares (10,000 units at $1.78), increasing direct ownership by 17% to 68,759 units (SEC Form 4)

$BIVI Leadership Updates

Live Leadership Updates

BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID

BioVie Announces the Appointment of a New Chief Medical Officer

BioVie Acquires Biopharma Assets from Privately Held NeurMedix

$BIVI Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cantor Fitzgerald initiated coverage on BioVie Inc. with a new price target

B. Riley Securities reiterated coverage on BioVie with a new price target

$BIVI Press Releases

Fastest customizable press release news feed in the world

BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

BioVie's Upcoming Parkinson's Disease Clinical Trial is Fully Funded

BioVie Inc. Announces Closing of Registered Direct Offering

$BIVI Financials

Live finance-specific insights

BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Recent Analyst Ratings for
$BIVI

$BIVI
Large Ownership Changes

$BIVI
SEC Filings

$BIVI
Market Insights

$BIVI
Insider Trading

$BIVI
Insider Purchases

$BIVI
Leadership Updates

$BIVI
Analyst Ratings

$BIVI
Press Releases

$BIVI
Financials